DDInter336 DDInter909
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Celecoxib {u} (Compound) palliates {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Imatinib
Celecoxib {u} (Compound) binds {v} (Gene) CA12
CA12 {u} (Gene) is bound by {v} (Compound) Imatinib
Celecoxib {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Imatinib
Celecoxib {u} (Compound) palliates {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Imatinib
Celecoxib {u} (Compound) binds {v} (Gene) CA12
CA12 {u} (Gene) regulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Imatinib
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Imatinib
Celecoxib {u} (Compound) binds {v} (Gene) CA9
CA9 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Imatinib
Celecoxib {u} (Compound) binds {v} (Gene) CA6
CA6 {u} (Gene) is bound by {v} (Compound) Zonisamide
Zonisamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Celecoxib {u} (Compound) binds {v} (Gene) ORM1
ORM1 {u} (Gene) interacts with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Imatinib
Celecoxib {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Imatinib
Celecoxib (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Imatinib (Compound)
Celecoxib (Compound) binds CA12 (Gene) and CA12 (Gene) is bound by Imatinib (Compound)
Celecoxib (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Celecoxib (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is associated with ABL1 (Gene) and ABL1 (Gene) is bound by Imatinib (Compound)
Celecoxib (Compound) binds CA12 (Gene) and CA12 (Gene) regulates ABL1 (Gene) and ABL1 (Gene) is bound by Imatinib (Compound)
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Imatinib
Celecoxib (Compound) binds CA9 (Gene) and CA9 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Imatinib (Compound)
Celecoxib (Compound) binds CA6 (Gene) and CA6 (Gene) is bound by Zonisamide (Compound) and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Celecoxib (Compound) binds ORM1 (Gene) and ORM1 (Gene) interacts with ALB (Gene) and ALB (Gene) is bound by Imatinib (Compound)
Celecoxib (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Imatinib